Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 216.66 billion. The enterprise value is 213.51 billion.

Market Cap	216.66B
Enterprise Value	213.51B

Important Dates

The last earnings date was Friday, May 23, 2025.

Earnings Date	May 23, 2025
Ex-Dividend Date	Jun 21, 2024

Share Statistics

Current Share Class	104.62M
Shares Outstanding	n/a
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	26.20M

Valuation Ratios

The trailing PE ratio is 58.30 and the forward PE ratio is 47.85.

PE Ratio	58.30
Forward PE	47.85
PS Ratio	18.05
PB Ratio	11.95
P/TBV Ratio	11.96
P/FCF Ratio	162.48
P/OCF Ratio	88.61
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 42.28, with an EV/FCF ratio of 160.12.

EV / Earnings	57.45
EV / Sales	17.79
EV / EBITDA	42.28
EV / EBIT	47.38
EV / FCF	160.12

Financial Position

The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.00.

Current Ratio	6.17
Quick Ratio	4.56
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.02
Interest Coverage	853.88

Financial Efficiency

Return on equity (ROE) is 22.26% and return on invested capital (ROIC) is 16.85%.

Return on Equity (ROE)	22.26%
Return on Assets (ROA)	15.13%
Return on Invested Capital (ROIC)	16.85%
Return on Capital Employed (ROCE)	24.43%
Revenue Per Employee	8.72M
Profits Per Employee	2.70M
Employee Count	1,377
Asset Turnover	0.64
Inventory Turnover	1.87

Taxes

In the past 12 months, Concord Biotech has paid 1.23 billion in taxes.

Income Tax	1.23B
Effective Tax Rate	24.85%

Stock Price Statistics

The stock price has increased by +31.52% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+31.52%
50-Day Moving Average	1,677.83
200-Day Moving Average	1,894.30
Relative Strength Index (RSI)	71.64
Average Volume (20 Days)	13,169

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 12.00 billion and earned 3.72 billion in profits. Earnings per share was 35.52.

Revenue	12.00B
Gross Profit	7.82B
Operating Income	4.52B
Pretax Income	4.95B
Net Income	3.72B
EBITDA	5.06B
EBIT	4.52B
Earnings Per Share (EPS)	35.52

Full Income Statement

Balance Sheet

The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion.

Cash & Cash Equivalents	3.18B
Total Debt	29.69M
Net Cash	3.15B
Net Cash Per Share	n/a
Equity (Book Value)	18.13B
Book Value Per Share	173.28
Working Capital	9.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.45 billion and capital expenditures -1.11 billion, giving a free cash flow of 1.33 billion.

Operating Cash Flow	2.45B
Capital Expenditures	-1.11B
Free Cash Flow	1.33B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.19%, with operating and profit margins of 37.66% and 30.97%.

Gross Margin	65.19%
Operating Margin	37.66%
Pretax Margin	41.21%
Profit Margin	30.97%
EBITDA Margin	42.19%
EBIT Margin	37.66%
FCF Margin	11.11%

Dividends & Yields

This stock pays an annual dividend of 8.75, which amounts to a dividend yield of 0.43%.

Dividend Per Share	8.75
Dividend Yield	0.43%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	24.63%
Buyback Yield	-0.01%
Shareholder Yield	0.42%
Earnings Yield	1.72%
FCF Yield	0.62%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4